Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis (NCT06609343)
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis (BRISK)
🩺 Plain-English Summary (8th-Grade Level)
Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysis patients. In this study, hemodialysis participants will receive bupropion tablet orally three times a week during routine dialysis procedure for consecutive 8 weeks. Study participants will complete a battery of questionnaires to self-report fatigue, cognition, and quality of life. The study team will collect biological specimens. All these procedures will be performed at the dialysis clinic during routine dialysis procedure.
Who can join: Review the eligibility criteria below.
Location: University Hospital Dialysis Medical Center (DMC) — San Antonio, Texas
Age range: 25 Years to 74 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University Hospital Dialysis Medical Center (DMC) — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (210) 567-4700
Email: nath@uthscsa.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in End Stage Renal Disease
- Light Therapy in End Stage Kidney Disease — Philadelphia, Pennsylvania
- Ferric Citrate in ESRD Pilot Project — Houston, Texas
- Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients — Washington D.C., District of Columbia
- Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease — New York, New York
- PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis — Washington D.C., District of Columbia
Explore by condition: All End Stage Renal Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.